Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy

Movement Disorders

Volumn 23, Issue 15, 2008, Pages 2202-2209

  Antonini, Angelo ^a   Berto, Patrizia ^b   Lopatriello, Stefania ^b   Tamma, Filippo ^c   Annemans, Lieven ^d   Chambers, Mike ^e  

^a PARKINSON INSTITUTE   (Italy)

^b Pbe Consulting   (Italy)

^c SAN PAOLO HOSPITAL   (Italy)

^d GHENT UNIVERSITY   (Belgium)

^e GE HEALTHCARE   (United Kingdom)

Author keywords

123I FP CIT; Cost effectiveness; DaTSCAN ; Essential tremor; Parkinson's disease; Parkinsonism; Single photon emission computed tomography (SPECT)

Indexed keywords

IOFLUPANE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 2 CARBOMETHOXY 8 (3 FLUOROPROPYL) 3 (4 IODOPHENYL)TROPANE; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; TROPANE DERIVATIVE;

ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DIFFERENTIAL DIAGNOSIS; DRUG COST; ECONOMIC EVALUATION; ESSENTIAL TREMOR; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; ITALY; NEUROIMAGING; PARKINSON DISEASE; PREVALENCE; PRIORITY JOURNAL; PROBABILITY; REIMBURSEMENT; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TREATMENT RESPONSE; ANALYSIS OF VARIANCE; COST BENEFIT ANALYSIS; ECONOMICS; EVALUATION; METABOLISM; METHODOLOGY; SCINTISCANNING;

ANALYSIS OF VARIANCE; COST-BENEFIT ANALYSIS; DIAGNOSIS, DIFFERENTIAL; ESSENTIAL TREMOR; EVALUATION STUDIES AS TOPIC; HUMANS; ITALY; PARKINSON DISEASE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 57749208525     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22278     Document Type: Article

References (23)

1. Morgante L, Rocca WA, Di Rosa AE, et al. Prevalence of Parkinson's disease and other types of parkinsonism: a door-to-door survey in three Sicilian municipalities. The Sicilian Neuro-Epidemiologic Study (SNES) Group. Neurology 1992;42:1901-1907.
2. Baldereschi M, Di Carlo A, Rocca WA, et al. Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging. Neurology 2000;55:1358-1363.
3. Mancini ML, Stracci F, Tambasco N, Sarchielli P, Rossi A, Calabresi P. Prevalence of essential tremor in the territory of Lake Trasimeno, Italy: results of a population-based study. Mov Disord 2007;22:540-545.
4. Cosentino M, Martignoni E, Michielotto D, et al. Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in Italy. BMC Health Serv Res 2005;5:26.
5. Meara J, Bhowmick BK, Hobson P. Accuracy of diagnosis in patients with presumed Parkinson's disease. Age Ageing 1999; 28:99-102.
6. Jankovic J, Rajput, AH, McDermott MP, Perl DP. The evolution of diagnosis in early Parkinson Disease. Arch Neurol 2000;57: 369-372.
7. Scherfler C, Schwarz J, Antonini A, et al. Role of DAT-SPECT in the diagnostic work up of Parkinsonism 2007;22:1229-1238.
8. Abi-Dargham A, Galdelman MS, DeErausquin GA, et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med 1996;37:1129-1133.
9. Seibyl JP, Marek K, Sheff K, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998; 39:1500-1508.
10. 123I]FP-CIT SPET in the demonstration of the dopaminergic de.cit in Parkinson's disease. Eur J Nucl Med 1997;24:68-71.
11. Booij J, Habraken JBA, Bergmans P, et al. Imaging of dopamine transporters with iodine-123-FP-CIT in healthy controls and patients with Parkinson's disease. J Nucl Med 1998;39:1879-1884.
12. Tissingh G, Booij J, Bergmans P, et al. Iodine-123-N-omega- fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med 1998;39:1143-1148.
13. 123I]FP-CIT SPECT. J Nucl Med 1999;40:753-761.
14. Catafau AM, Tolossa E. DaTSCAN® CUPS Study Group. Impact of dopamine transporter SPECT using 123-I-Iofluapne on diagnosis and management of patients with clinically uncertain Parkinson syndromes. Mov Disord 2004;14:1175-1182.
15. Annemans L, Chambers M. Economic evaluation of DaTSCAN® in the diagnosis of Parkinsonism. Value in Health 2003;6:766. [Abstract].
16. 123I-FP-CIT SPECT imaging: the FP-CIT study group. Mov Disord 2000;15:503-510.
17. ISTAT (Istituto Nazionale di Statistica). Cause di morte, anno 2002.www.istat.it.
18. GIOFIL databse,www.giofil.it, accessed 28th Feb 2005.
19. Ministry of Health. Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del SSN e relative tariffe GU n 216 of 14/11/1996: DM 22/07/1996.
20. Conferenza delle Regioni e Province Autonome. Tariffa Unica Convenzionale per le prestazioni di assistenza ospedaliera, 5 giugno 2003.
21. Gold MR, Patrick DL, Torrance GW, et al. Identifying and valuing outcomes. In: Gold MR, Russell LB, Seigel JE, Weinstein MC, editors. Cost-effectiveness in health and medicine. New York: Oxford University Press; 1996. p 82-134.
22. Hughes AJ, Daniel SE, Lees AJ. Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease. Neurology 2001;57: 1497-1499.
23. Dodel RC, Höffken H, Möller JC, et al. Dopamine transporter imaging and SPECT in diagnostic workup of Parkinson's disease: a decision-analytic approach. Mov Disord 2003;18(Suppl 7):52-62.